Zamora, AnaGandioso, AlbertMassaguer i Vall-llovera, AnnaBuenestado, SilviaCalvis, CarmeHernández, José LuisMitjans, FrancescRodríguez, VenancioRuiz, JoséMarchán Sancho, Vicente2018-09-282019-09-062018-09-061860-7179https://hdl.handle.net/2445/124909A novel conjugate between a cyclometalated platinum(II) complex with dual antiangiogenic and antitumor activity and a cyclic peptide containing the RGD sequence (-Arg-Gly-Asp-) has been synthesized by combining solid- and solution-phase methodologies. Although peptide conjugation rendered a non-cytotoxic compound in all tested tumor cell lines (± αV β3 and αV β5 integrin receptors), the antiangiogenic activity of the Pt-c(RGDfK) conjugate in human umbilical vein endothelial cells at sub-cytotoxic concentrations opens the way to the design of a novel class of angiogenesis inhibitors through conjugation of metallodrugs with high antiangiogenic activity to cyclic RGD-containing peptides or peptidomimetic analogues.8 p.application/pdfeng(c) Wiley-VCH, 2018AngiogènesiCàncerPèptidsCompostos organometàl·licsNeovascularizationCancerPeptidesOrganometallic compoundsinfo:eu-repo/semantics/article6822002018-09-28info:eu-repo/semantics/openAccess29932312